Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951411 | 1.00 | TRPV4 (0.34) | TRPV4MAOAMAOBENPP2CYP11B1 | |
| SCHEMBL2732608 | 0.90 | GRM4 (0.33) | ENPP2AR | |
| SCHEMBL16052048 | 0.84 | FFAR4 (0.38) | TRPV4MAOAMAOBENPP2CYP11B1 | |
| SCHEMBL29956185 | 0.84 | FFAR4 (0.38) | TRPV4MAOAMAOBENPP2CYP11B1 | |
| SCHEMBL18105634 | 0.80 | SLC22A12 (0.38) | TRPV4MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL177542 | 0.79 | AR (0.44) | SLC22A12KDM4EALDH1A1NPSR1RXFP1 | |
| SCHEMBL23191268 | 0.78 | ENPP2 (0.48) | ENPP2ALDH1A1FFAR1AR | |
| SCHEMBL30537828 | 0.78 | ENPP2 (0.48) | ENPP2ALDH1A1FFAR1AR | |
| SCHEMBL15031886 | 0.78 | ALDH1A1 (0.38) | MAOAMAOBENPP2KDM4EALDH1A1 | |
| SCHEMBL29956199 | 0.78 | AR (0.44) | ENPP2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117946080-A | Organic molecules, in particular for organic optoelectronic devices | 三星显示有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2445883-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8101632-B2 | 5-furopyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2011116951-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
| WO-2010150192-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20090318439-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2125826-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | Albany Molecular Research, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008086409-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | TRPV4 4802/4885MAOA 4781/4885MAOB 4603/4885 |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | TRPV4 3380/4885MAOA 284/4885MAOB 343/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TRPV4 3399/4885MAOA 2527/4885MAOB 1582/4885 |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | TRPV4 2277/4885MAOA 1110/4885MAOB 758/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | TRPV4 2277/4885MAOA 1110/4885MAOB 758/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TRPV4 3399/4885MAOA 2527/4885MAOB 1582/4885 |
| US-20090318439-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | MCHR1, PRMT5, PRMT1 | TRPV4 742/4885MAOA 1818/4885MAOB 1545/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | TRPV4 4802/4885MAOA 4781/4885MAOB 4603/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | TRPV4 4802/4885MAOA 4781/4885MAOB 4603/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | TRPV4 4802/4885MAOA 4781/4885MAOB 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.